Latest Industry News & Trends
Market Scope provides comprehensive coverage of the ophthalmic market. Our news stories are a combination of public and proprietary content ranging from coverage of international meetings, surgeon survey results and trends, analysis of company financial reports and public medical registries, press releases, and interviews with executives. Register today to receive free weekly email updates, our top data chart, surgeon poll results, and much more. Locked content can be accessed through a subscription to our ophthalmic industry newsletters.
Clinical Trial News
Acelyrin’s Izokibep Misses Endpoints in Phase IIb/III Uveitis Trial
Acelyrin reported Dec. 10 that izokibep, an inhibitor of interleukin-17A, missed its endpoints in a Phase IIb/III trial in non-infectious, non-anterior uveitis. The company said it would drop izoki...
Eyenovia Scraps Phase III Study of Low-Dose Atropine Candidate in Myopia
Eyenovia reported Nov. 15 that it would scrap the Phase III CHAPERONE trial of low-dose atropine in pediatric myopia after an independent data review committee determined that the trial is not meet...
Clinical Trial Updates for Ophthalmic Candidates, December 2024
Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.
Outlook’s Lytenava Misses Endpoint vs. Ranibizumab in Topline Results
Outlook Therapeutics reported Nov. 27 that its ophthalmic bevacizumab candidate Lytenava (ONS-5010) did not meet its non-inferiority endpoint in topline results from the NORSE EIGHT trial vs. ranib...
US FDA Gives Green Light to Phase I/II Trial of Sumitomo Retinal Cell Implant for RP
Japan’s Sumitomo Pharma announced Nov. 29 that the US FDA had cleared its investigational new drug (IND) application for a Phase I/II trial of its allogeneic retinal sheet derived from induced plur...
Outlook’s Lytenava Misses Endpoint vs. Ranibizumab in Topline Results
Outlook Therapeutics reported Nov. 27 that its ophthalmic bevacizumab candidate Lytenava (ONS-5010) did not meet its non-inferiority endpoint in topline results from the NORSE EIGHT trial vs. ranib...
Nicox Chooses Higher Dose of NCX 470 to Advance in Phase III Glaucoma Trials
France’s Nicox announced Nov. 19 that it had chosen the higher dose of NCX 470 ophthalmic solution to advance in the Phase III Mont Blanc trial in glaucoma. The company said both doses tested—0.065...
MeiraGTx to Submit UK Marketing Application for LCA4 Candidate Under ‘Exceptional Circumstances’
MeiraGTx, with offices in London and New York, announced Nov. 13 that it would submit a marketing authorization application in the UK under “exceptional circumstances” for AAV-AIPL1, its gene thera...
Eyenovia Scraps Phase III Study of Low-Dose Atropine in Myopia After Endpoint Missed
Eyenovia reported Nov. 15 that it would scrap the Phase III CHAPERONE trial of low-dose atropine in pediatric myopia after an independent data review committee determined that the trial is not meet...
Clinical Trial Updates for Ophthalmic Candidates, November 2024
Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.
November 2024 Ophthalmic News Briefs
Heidelberg Engineering announced Oct. 14 that the US FDA had granted 510(k) clearance to its Flex Module for the Spectralis diagnostic imaging platform. The Flex Module mounts the Spectralis to a m...
Alkeus’ Oral Gildeuretinol for GA Shows Positive Topline Results in Phase III
Alkeus Pharmaceuticals reported positive topline results on Oct. 23 from the Phase III SAGA trial of gildeuretinol acetate (ALK-001), a once-daily oral therapy candidate targeting geographic atroph...
Preliminary Results Show Prima Implant Allows for Functional Vision in Advanced GA Patients
Science Corporation, of Alameda, California, reported Oct. 22 preliminary results that showed its Prima retinal implant allowed for functional vision in patients who had lost their central visual f...
Retina Specialists Grapple with Functional Endpoints in Clinical Trials
European regulators’ repeated rejection of Syfovre made one thing very clear to retina specialists at Euretina: “Treatment should have an impact on everyday function,” said Thomas Ach, MD (Germany)...
ViaLase Releases Latest Glaucoma Laser Data at ESCRS Congress
Rick Lewis, MD, chief medical officer at ViaLase, provided an update at the 2024 ESCRS congress on the ViaLuxe glaucoma laser, including the system’s most recent clinical trial results. The ViaLuxe...
Clinical Trial Updates for Ophthalmic Candidates, October 2024
Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.
October 2024 Ophthalmic News Briefs
Oculus has announced the addition of frequency doubling perimetry (FDP) to its Easyfield VR visual field diagnostic headset. The German ophthalmic diagnostic company, with US headquarters in Arling...
Rayner Begins US Study of RayOne Galaxy Trifocal Spiral IOL
UK-based Rayner reported Oct. 1 that the first RayOne Galaxy lenses had been implanted in the US as part of an FDA investigational device exemption (IDE) study. Rayner describes the Galaxy, a trifo...
US FDA Removes Clinical Hold on Ocugen’s IND for OCU200 in DME
Ocugen announced Oct. 9 that the US FDA had lifted its clinical hold on the investigational new drug (IND) application for a Phase I trial of OCU200, a recombinant fusion protein consisting of tums...
Oculis Shuts Down Phase III Trial of OCS-01 Due to Third-Party Administrative Error
Swiss company Oculis reported Aug. 27 in its Q2-2024 financial statement that it was shutting down the Phase III OPTIMIZE-2 trial of its OCS-01 eye drop candidate for postsurgical inflammation and ...
Clinical Trial Updates for Ophthalmic Candidates, September 2024
Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.
September 2024 Ophthalmic News Briefs
Bausch + Lomb is working with Goldman Sachs to explore a sale of the company, the Financial Times reported Sept. 14, with private equity the most likely buyer. The move is being evaluated as a way ...
Livionex’ Cataract Drop Candidate to Advance After New Analysis of Study Results
A new analysis of 2008 clinical study data has given a boost to Livionex’ topical drop candidate for cataracts, the John Moran Eye Center reported Aug. 16. The drop, called C-KAD, is a formulation ...
OcuDyne Reports Positive Pilot Study Results Using Ophthalmic Artery Angioplasty in GA
OcuDyne, of Brooklyn Park, Minnesota, reported Sept. 9 that it had successfully completed a pilot study using its Optic System to perform ophthalmic artery angioplasty in patients with geographic a...
US FDA Gives Go-Ahead to Trial of BlueRock’s Cell Therapy Candidate for Photoreceptor Diseases
Bayer subsidiary BlueRock Therapeutics announced Sept. 3 that the US FDA had cleared its investigational new drug application for a Phase I/IIa trial of OpCT-001, an induced pluripotent stem cell (...
Injectsense Completes First Human Implantation of its Ultraminiaturized IOP Sensor
Injectsense, of Emeryville, California, announced Aug. 27 that it had implanted its first ultraminiature wireless sensor for measuring intraocular pressure (IOP). Glaucoma specialist Juan Mura, MD,...
Oculis Shuts Down Phase III Trial of OCS-01 Due to Third-Party Administrative Error
Swiss company Oculis reported Aug. 27 in its Q2-2024 financial statement that it was shutting down the Phase III OPTIMIZE-2 trial of its OCS-01 eye drop candidate for postsurgical inflammation and ...
Health Canada Gives Green Light to Phase III Trial of Ocugen’s Gene Therapy Candidate for RP
Ocugen announced Aug. 26 that Health Canada had cleared the way for a Canadian Phase III trial of OCU400, a modifier gene therapy candidate for retinitis pigmentosa (RP). Ocugen, of Malvern, Pennsy...
Livionex’ Cataract Drop Candidate to Advance After New Analysis of Study Results
A new analysis of 2008 clinical study data has given a boost to Livionex’ topical drop candidate for cataracts, the John Moran Eye Center reported Aug. 16. The drop, called C-KAD, is a formulation ...
Acelyrin Shifts Pipeline to Focus on TED Candidate, Lays Off About 40 Workers
Acelyrin reported Aug. 13 that it would reduce its workforce and shift its pipeline strategy to prioritize lonigutamab, its candidate for thyroid eye disease (TED). The announcement came amid posit...
Clinical Trial Updates for Ophthalmic Candidates, August 2024
Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.
Clinical Trial Updates for Ophthalmic Candidates, July 2024
Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.
July 2024 Ophthalmic News Briefs
Bausch + Lomb announced July 23 that it had acquired dry eye diagnostic company Trukera Medical from its private equity owner, AccelMed Partners, and other shareholders. No financial details were d...
Okyo Pharma to Initiate Phase II Trial for OK-101 in Neuropathic Corneal Pain
London’s Okyo Pharma announced July 11 that it would advance OK-101 into a Phase II clinical trial of neuropathic corneal pain (NCP). The US FDA cleared the investigational new drug (IND) applicati...
US FDA Gives Green Light to Trial of 4DMT’s Gene Therapy Candidate for GA
4D Molecular Therapeutics announced June 24 that the US FDA had cleared its investigational new drug application for a Phase I clinical trial of 4D-175, an intravitreal gene therapy candidate targe...
Skye Drops Glaucoma Program After Phase IIa Failure, Shifts Focus to Obesity
Skye Bioscience reported June 10 that it was discontinuing its ophthalmology program after its synthetic cannabinoid derivative SBI-100, a glaucoma drop candidate, failed to meet its Phase IIa prim...
Clinical Trial Updates for Ophthalmic Candidates, June 2024
Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.
June 2024 Ophthalmic News Briefs
Japan’s Nidek announced June 3 that it had launched the RS-1 Glauvas OCT system. The device is CE marked as a Class IIa device. Nidek said the RS-1 Glauvas’ streamlined workflow and advanced analyt...
Skye Drops Glaucoma Program After Phase IIa Failure, Shifts Focus to Obesity
Skye Bioscience reported June 10 that it was discontinuing its ophthalmology program after its synthetic cannabinoid derivative SBI-100, a glaucoma drop candidate, failed to meet its Phase IIa prim...
US FDA Gives Green Light to Trial of Avirmax’ Gene Therapy Candidate for Wet AMD with PCV
Avirmax Biopharma announced May 30 that the US FDA had cleared its investigational new drug application for a Phase I/IIa clinical trial of its intravitreal gene therapy candidate targeting wet age...
Dopavision Sees Positive Results in Trial of Photobiomodulation for Myopia
Germany’s Dopavision reported May 28 that its MyopiaX photobiomodulation system targeting myopia showed signals of clinical effect on the rate of progression at six months in a proof-of-concept tri...
US FDA Gives Green Light to Phase Ib Trial of Drug Farm’s Oral ALPK1 Inhibitor in ROSAH Patients
Drug Farm, of Shanghai, China, announced May 17 that the US FDA had cleared its investigational new drug (IND) application for a Phase Ib trial of its DF-003, an oral alpha kinase 1 (ALPK1) inhibit...
Ophthalmic Companies Use ARVO Meeting to Boost Research
Many companies participate in ARVO’s annual meeting to catch the attention of external researchers and propel their research program or clinical trials forward. Two such companies in 2024 were John...
Clinical Trial Updates for Ophthalmic Candidates, May 2024
Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.
EyePoint’s Duravyu Misses Primary Endpoint in Phase II Trial in NPDR
EyePoint Pharmaceuticals reported May 6 that Duravyu (vorolanib intravitreal insert) missed its primary endpoint of improvement in Diabetic Retinopathy Severity Scale score in patients with non-pro...
Aldeyra Plans US Pivotal Trial for Methotrexate Injection in RP
Aldeyra Therapeutics said April 25 that it planned to initiate a pivotal Phase II/III trial for ADX-2191 (methotrexate injection) in patients with retinitis pigmentosa due to rhodopsin misfolding m...
US FDA Accepts IND for Eluminex’ Tri-specific Antibody Candidate for DME
China-headquartered Eluminex Biosciences announced April 30 that the US FDA had accepted its investigational new drug (IND) application for EB-105, a tri-specific fusion antibody candidate for diab...
Lenz Reports Positive Topline Phase III Data in Presbyopia, Plans NDA Submission in Mid-2024
Lenz Therapeutics reported April 3 positive topline results from its Phase III CLARITY trials of LNZ100 and LNZ101 for presbyopia. LNZ100 and LNZ101 are preservative free, single-use, once-daily ey...
Clinical Trial Updates for Ophthalmic Candidates , April 2024
Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.
Nanoscope Reports Positive Results for RP Optogenetic Therapy
Nanoscope Therapeutics on March 26 reported positive topline results from its two-year Phase IIb clinical trial of MCO-010, an ambient-light-activatable optogenetic monother-apy to restore vision i...
April 2024 Ophthalmic News Briefs
Alexion, the rare disease unit of AstraZeneca, announced March 25 that the US FDA had approved its long-acting C5 complement inhibitor Ultomiris (ravulizumab-cwvz) for adults with neuromyelitis opt...
US FDA Clears IND Amendment with New Mobility Test for Phase III Trial of Ocugen RP Gene Therapy Candidate
Ocugen announced April 8 that the US FDA had cleared the company’s investigational new drug (IND) amendment to initiate a Phase III clinical trial of OCU400, a modifier gene therapy candidate for r...
Lenz Reports Positive Topline Phase III Data in Presbyopia, Plans NDA Submission in Mid-2024
Lenz Therapeutics reported April 3 positive topline results from its Phase III CLARITY trials of LNZ100 and LNZ101 for presbyopia. LNZ100 and LNZ101 are preservative-free, single-use, once-daily ey...
Aldeyra Outlines New Reproxalap Trial, Aims to Resubmit NDA in Dry Eye
Aldeyra Therapeutics on March 28 outlined its new clinical development plan for reproxalap eye drops, with the goal of resubmitting its new drug application (NDA) to the US FDA. The company said it...
Nanoscope Reports Positive Results for RP Optogenetic Therapy, Plans to file BLA in H2-2024
Nanoscope Therapeutics on March 26 reported positive topline results from its two-year Phase IIb clinical trial of MCO-010, an ambient-light-activatable optogenetic monotherapy to restore vision in...
Okyo’s Dry Eye Candidate Hits Multiple Phase II Endpoints, Including Ocular Pain Relief
London’s Okyo Pharma released additional findings on March 22 from its Phase II trial of topical dry eye candidate OK-101. The company had previously reported statistically significant improvements...
Belite Bio Applies to Japanese Regulators for Clinical Trial of Oral Stargardt Candidate
Belite Bio announced March 22 that it had applied to Japan’s Pharmaceuticals and Medical Devices Agency for clearance to conduct a clinical trial of tinlarebant, its oral treatment candidate for St...
OcuTerra’s Eye Drop Candidate for DR Misses Endpoints in Phase II
OcuTerra Therapeutics announced March 14 that nesvategrast (OTT166 5%), its eye drop candidate for diabetic retinopathy, did not meet its primary or key secondary efficacy endpoints in the Phase II...
US FDA Gives Green Light to Phase I Trial of Fuchs’ Candidate from Design Therapeutics
Design Therapeutics reported March 19 in its 2023 financial statement that the US FDA had cleared its investigational new drug (IND) application for a clinical trial of DT-168 in Fuchs’ endothelial...
Clinical Trial Updates for Ophthalmic Candidates, March 2024
Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.
Eversight Partners with Emmecell to Advance Corneal Cell Therapies
Global nonprofit eye bank Eversight and Emmecell announced Feb. 20 that they would collaborate to advance cell therapies for corneal treatment. Emmecell, of Menlo Park, California, is developing EO...
Phase II/III Trial of Innovent’s TED Candidate Meets Primary Endpoint
China’s Innovent Biologics announced Feb. 19 that the primary endpoint had been achieved in the company’s Phase II/III trial of IBI311, a recombinant anti-insulin-like growth factor 1 receptor (IGF...
Japan Eases Clinical Trial Requirements for Foreign Drugmakers in Growing Trend
Japan has removed the requirement that foreign drugmakers conduct a Phase I clinical trial in Japan before Japanese individuals participate in Phase III multiregional clinical trials (MRCT) for reg...
Clinical Trial Updates for Ophthalmic Candidates , February 2024
Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.
4DMT Gene Therapy Candidate Reduces Treatment Burden in Phase II Wet AMD Trial
4D Molecular Therapeutics reported Feb. 3 that it had seen positive topline results from the Phase II PRISM trial evaluating 4D-150, an intravitreal gene therapy candidate, in wet age-related macul...
February 2024 Ophthalmic News Briefs
Amneal Pharmaceuticals announced Jan. 10 that it had received US FDA approval for and launched generic fluorometholone eye drops. The product is indicated for the treatment of corticosteroid-respon...
US FDA Gives Green Light to Phase II Trial of Okyo’s OK-101 in the First IND Cleared for Neuropathic Corneal Pain
London’s Okyo Pharma announced Feb. 9 that the US FDA had cleared its investigational new drug (IND) application for topical candidate OK-101 in neuropathic corneal pain—a first for that indication...
Sylentis’ Topical Candidate for Sjögren’s Dry Eye Misses Endpoints in Phase III
Spain’s Sylentis, a PharmaMar Group company, announced Feb. 9 that tivanisiran, a topical treatment candidate for dry eye disease associated with Sjögren’s syndrome, did not meet primary efficacy e...
Ascidian’s Stargardt Candidate is First RNA Exon Editor to Gain FDA’s Green Light for Trial
Ascidian Therapeutics announced Jan. 29 that the US FDA had cleared a Phase I/II clinical trial for its ACDN-01 RNA exon editor for Stargardt disease and other ABCA4 retinopathies. It’s the first g...
Iuvo BioScience Acquires Promedica International, Broadening Ophthalmic CRO Expertise
Rochester, New York-based Iuvo BioScience, a clinical research organization (CRO) that specializes in ophthalmology, reported Jan. 18 that it had acquired privately held Promedica International, an...
Clinical Trial Updates for Ophthalmic Candidates, January 2024
Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.
Alcon Reports Positive Topline Results in Phase III for AR-15512 in Dry Eye
Alcon reported Jan. 9 that it saw positive topline results from two pivotal Phase III clinical trials (COMET-2 and COMET-3) evaluating the efficacy and safety of AR-15512 in dry eye. AR-15512, a TR...
Alcon Reports Positive Topline Results in Phase III for AR-15512 in Dry Eye
Alcon reported Jan. 9 that it saw positive topline results from two pivotal Phase III clinical trials (COMET-2 and COMET-3) evaluating the efficacy and safety of AR-15512 in dry eye. AR-15512, a TR...
Annexon, US FDA Agree on Preservation of Vision Endpoint for Phase III Trial of GA Candidate
Annexon announced Dec. 20 that the US FDA had agreed to a Phase III registrational program for ANX007, a first-in-class C1q and classical complement inhibitor, for geographic atrophy (GA) that incl...
Tarsus Reports Positive Topline Results from Phase IIa Trial of TP-03 for MGD with Demodex
Tarsus Pharmaceuticals, of Irvine, California, reported Dec. 11 that TP-03 (lotilaner ophthalmic solution, 0.25%) saw positive topline results in the Phase IIa Ersa trial of patients with meibomian...
Oxurion to File for Bankruptcy After DME Candidate Misses Phase II Endpoint
Belgium’s Oxurion reported Nov. 20 that it would take the steps necessary to file for bankruptcy after its plasma kallikrein inhibitor THR-149 failed to reach its primary endpoint of improvement in...
EyePoint’s Anti-VEGF Sustained-Release Implant for Wet AMD Meets All Endpoints in Phase II Trial
EyePoint Pharmaceuticals reported Dec. 4 that EYP-1901, a sustained-release anti-VEGF implant candidate, met its primary endpoint and all secondary endpoints in the Phase II DAVIO 2 trial in wet ag...
US FDA Rejects Aldeyra’s Reproxalap for Dry Eye, Asks for New Trial to Show Symptom Relief
Aldeyra Therapeutics reported Nov. 27 that the US FDA had, as expected, issued a complete response letter rejecting the company’s new drug application (NDA) for topical reproxalap as a treatment fo...
Clinical Trial Updates for Ophthalmic Candidates, December 2023
Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.
December 2023 Ophthalmic News Briefs
Enzene Biosciences, based in Pune, India, announced in November that it had launched a ranibizumab biosimilar for the treatment of wet age-related macular degeneration (AMD). The product references...
EyePoint’s Sustained-Release Anti-VEGF Implant for Wet AMD Meets All Endpoints in Phase II
EyePoint Pharmaceuticals reported Dec. 4 that EYP-1901, a sustained-release anti-VEGF implant candidate, met its primary endpoint and all secondary endpoints in the Phase II DAVIO 2 trial in wet ag...
US FDA Gives Green Light to Phase II Trial of VivaVision’s Candidate for Post-Cataract Inflammation
VivaVision, of Wenzhou, China, announced Dec. 4 that the US FDA had cleared a Phase II trial of its VVN461 eye drop candidate for postoperative inflammation after cataract surgery. VVN461 is a pote...
US FDA Rejects Aldeyra’s Reproxalap for Dry Eye, Asks for New Trial to Show Symptom Relief
Aldeyra Therapeutics reported Nov. 27 that the US FDA had, as expected, issued a complete response letter rejecting the company’s new drug application (NDA) for topical reproxalap as a treatment fo...
Oxurion to File for Bankruptcy After DME Candidate Misses Phase II Endpoint
Belgium’s Oxurion reported Nov. 20 that it would take the steps necessary to file for bankruptcy after its plasma kallikrein inhibitor THR-149 failed to reach its primary endpoint of improvement in...
Outlook Plans New Clinical Trial for Lytenava After Meeting with US FDA
Outlook Therapeutics reported Nov. 2 that it plans to hold another clinical trial of Lytenava, an ophthalmic formulation of bevacizumab, for wet age-related macular degeneration (AMD), in the wake ...
Clinical Trial Updates for Ophthalmic Candidates, November 2023
Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.
US FDA Gives Green Light to Trial of Inflammasome’s Sustained-Release Implant for GA
Inflammasome Therapeutics announced Nov. 13 that the US FDA had cleared a Phase I/II trial for its inflammasome inhibitor in a sustained-release ocular implant for geographic atrophy (GA), the adva...
Kodiak Will Restart its Tarcocimab Program After Strong Results in Phase III DR Trial
Kodiak Sciences announced Nov. 6 that it would restart its tarcocimab tedromer development program after strong positive results from a Phase III trial in diabetic retinopathy (DR). The Palo Alto, ...
Chinese Regulators Give Green Light to Skyline for Trial of Gene Therapy Candidate for Wet AMD
China’s Skyline Therapeutics announced Oct. 19 that the National Medical Products Administration had cleared its investigational new drug application for a clinical trial of SKG0106, a one-time int...
US FDA Clears IND for Trial of Endogena’s RPE Regeneration Candidate in GA
Swiss company Endogena Therapeutics announced Oct. 24 that the US FDA had cleared its investigational new drug (IND) application for a clinical trial of EA-2351, a regenerative treatment candidate ...
Roche Drops Development of Oral Drug Candidate for DR
Swiss drugmaker Roche reported in its Q3-2023 earnings call on Oct. 19 that it had ended development of vicasinabin (RG7774), an oral candidate for non-proliferative diabetic retinopathy, after com...
Clinical Trial Updates for Ophthalmic Candidates, October 2023
Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.
October 2023 Ophthalmic News Briefs
Théa Pharma, the US subsidiary of France’s Laboratoires Théa, announced the launch Sept. 26 of once-daily Iyuzeh (latanoprost ophthalmic solution) 0.005% in the US market. Iyuzeh is the first prese...
First Patient Dosed in Phase III Trial of Innovent’s Anti-VEGF, Anti-Complement Candidate for Wet AMD
China’s Innovent Biologics announced Oct. 8 that the first patient had been dosed in a Phase III trial of efdamrofusp alfa (IBI302), a recombinant fully human anti-VEGF and anti-complement bispecif...
Two-Year Results for Izervay Show Continued Slowing of GA Growth
Iveric Bio, an Astellas company, reported on Sept. 18 positive 24-month topline results from the Phase III GATHER2 trial of Izervay (avacincaptad pegol), its treatment for geographic atrophy (GA) s...
Clinical Trial Updates for Ophthalmic Candidates, September 2023
Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.
September 2023 Ophthalmic News Briefs
Carl Zeiss Meditec announced Aug. 23 that more than 8 million eyes had been treated with the company’s SMILE procedure through the first half of 2023. SMILE, short for small-incision lenticule extr...
Neurophth Gets Green Light from Australian Regulators for Trial of Ophthalmic Gene Therapy Candidate
Neurophth Therapeutics announced Sept. 6 that the Australian Therapeutic Goods Administration had cleared its gene therapy candidate NFS-05 for clinical trials targeting autosomal dominant optic at...
EMA Gives Green Light to Phase Ib Trial of ViGeneron’s Gene Therapy Candidate for RP
Germany’s ViGeneron announced Aug. 22 that the European Medicines Agency (EMA) had approved its clinical trial application for VG901, a gene therapy candidate targeting CNGA1-associated retinitis p...
Tarsier’s Dazdotuftide Misses Phase III Primary Endpoint, Shows Promise for Uveitic Glaucoma
Israel’s Tarsier Pharma reported Aug. 23 that its TRS01 (dazdotuftide) eye drops failed to meet the primary inflammation endpoint in a Phase III trial in patients with active noninfectious anterior...
Clinical Trial Updates for Ophthalmic Candidates, August 2023
Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.
Want to Read the Full Article?
Already Have an Account?
Register A Corporate Account
A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.